Midazolam

Generic Name
Midazolam
Brand Names
Buccolam, Busulfex, Nayzilam, Seizalam
Drug Type
Small Molecule
Chemical Formula
C18H13ClFN3
CAS Number
59467-70-8
Unique Ingredient Identifier
R60L0SM5BC
Background

Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia.

This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older. Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence.

Indication

Midazolam has different indications depending on its formulation by the FDA.

Nasal

For the nasal spray formulation, midazolam is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

Intravenous

For the intravenous injection formulation, midazolam is indicated as an agent for sedation/anxiolysis/amnesia and prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other CNS depressants. The sedative, anxiolytic and amnestic use of midazolam can also be employed pre-operatively. It can also be indicated for induction of general anesthesia, before administration of other anesthetic agents or as a component of intravenous supplementation of nitrous oxide and oxygen for a balanced anesthesia. A relatively narrower dose range of midazolam and a shorter period of induction can be achieved if midazolam is combined with narcotic premedication. Finally, midazolam can be indicated as a continous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting.

Intramuscular

For the intramusuclar injection formulation, midazolam is indicated for preoperative sedation/anxiolysis/amnesia or for treatment of status epilepticus in adults.

Oral

Midazolam syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. It is only approved in monitored settings only and not for chronic or home use.

In Europe, a buccal formulation of midazolam is also approved for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

Associated Conditions
Epileptic seizure, Status Epilepticus
Associated Therapies
Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy

A Study of Imlunestrant (LY3484356) in Healthy Women

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-08-22
Last Posted Date
2023-01-13
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
20
Registration Number
NCT05509816
Locations
🇺🇸

LabCorp CRU, Inc., Dallas, Texas, United States

The Effects of Sedatives on Tobacco Use Disorder Version 2

First Posted Date
2022-08-18
Last Posted Date
2024-07-08
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
52
Registration Number
NCT05505630
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-07-29
Last Posted Date
2022-11-08
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
18
Registration Number
NCT05480488
Locations
🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

Comparison of Pharmacological and Non-Pharmacological Interventions For Alleviating Preoperative Anxiety In Children

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2022-07-21
Last Posted Date
2024-06-26
Lead Sponsor
Aga Khan University
Target Recruit Count
84
Registration Number
NCT05469412
Locations
🇵🇰

Aga Khan University Hospital, Karachi, Sindh, Pakistan

The Role of Remazolam in Reducing the Incidence of Postoperative Delirium in Elderly Patients

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2022-07-20
Last Posted Date
2024-01-25
Lead Sponsor
Fang Jun
Target Recruit Count
131
Registration Number
NCT05466279
Locations
🇨🇳

Zhejiang Cancer Hospital, Hanzhou, China

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-07-20
Last Posted Date
2022-07-20
Lead Sponsor
Concert Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT05467709
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Comparison of Postoperative Delirium in Elders Anaesthetised With Midazolam and Without Midazolam

Completed
Conditions
Interventions
First Posted Date
2022-07-13
Last Posted Date
2022-07-18
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
11927
Registration Number
NCT05456230
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

First Posted Date
2022-07-06
Last Posted Date
2023-04-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
32
Registration Number
NCT05445232
Locations
🇺🇸

Covance Dallas, Dallas, Texas, United States

🇺🇸

Covance Clinical Research Unit, Daytona Beach, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath